360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Zetia

Type: Product

Name: Zetia

First reported 21 hours ago - Updated 21 hours ago - 1 reports

ZOCOR

Pick Your Poison: Overweight or High Cholesterol

Keep track of the stocks that matter to you.Help yourself with the Fool's FREE and easy new watchlist service today.Overweight and have high cholesterol? You may have to pick one to work on at a time, according to data from the lab of John Thyfault, an ... [Published Motley Fool - 21 hours ago]

Entities: ZOCOR, Cholesterol, Overweight, Statins

First reported May 15 2013 - Updated May 15 2013 - 1 reports

FDA Food & Drug Administration

FDA Approves Dangerous and Worthless Cholesterol Drug

, the FDA approved a Big Pharma Cartel founding member Merck drug Liptruzet. Liptruzet is a combination drug of Zetia and Lipitor. I wrote to you about the failure of Zetia in three separate blog posts. They can all be found by clicking here: htt ... [Published Health Impact News - May 15 2013]

Entities: Zetia, FDA Food & Drug Administration, Drugs, Cholesterol

First reported May 13 2013 - Updated May 13 2013 - 1 reports

Are You Taking This Dangerous Drug?

, the FDA approved a Big Pharma Cartel founding member Merck drug Liptruzet. Liptruzet is a combination drug of Zetia and Lipitor. I wrote to you about the failure of Zetia in three separate blog posts. They can all be found by clicking here. Zetia is ... [Published LewRockwell.com - May 13 2013]

Entities: Zetia, Drugs, Lipitor, Cholesterol

First reported May 09 2013 - Updated May 10 2013 - 4 reports

The FDA Approval Of Merck's Cholesterol Lowerer, Liptruzet, Doesn't Help Its Credibility

Josh Bloom recently wrote a very provocative piece entitled: "How can Merck look itself in the mirror?" Bloom is concerned that this once greatly admired pharmaceutical company has lost its way by bringing to market the LDL cholesterol lowering drug, ... [Published Forbes.com - May 10 2013]

Entities: Cholesterol, Zetia, Drugs, Statins, Vytorin

First reported May 07 2013 - Updated May 08 2013 - 4 reports

FDA Approves Merck’s Cholesterol Combo; Critics Cry Foul

In a move that drew disgruntled comments from FDA advisors, the agency on Friday approved Merck?s Liptruzet, a combination of Merck?s Zetia and Pfizer?s Lipitor, to treat hyperlipidemia. Merck trumpeted that Liptruzet can ?powerfully? lower low-density ... [Published FDA News - May 08 2013]

Entities: Merck & Co Inc, Cholesterol, Zetia, Lipoprotein, Lipitor

First reported May 06 2013 - Updated May 07 2013 - 6 reports

Lipitor

FDA Approves Merck’s Cholesterol Combo; Critics Cry Foul

In a move that drew disgruntled comments from FDA advisors, the agency on Friday approved Merck’s Liptruzet, a combination of Merck’s Zetia and Pfizer’s Lipitor, to treat hyperlipidemia. ... [Published FDA News - May 07 2013]

Entities: Merck & Co Inc, Cholesterol, Zetia, Lipitor

First reported May 05 2013 - Updated May 05 2013 - 1 reports

Merck & Co Inc

FDA Approves Cholesterol Drug Liptruzet

The United States Food and drug Administration has announced the approval on Friday of a drug developed by Merck that reduces a person’s cholesterol. Liptruzet is a combination drug that combines Merck’s Zetia and the generic form of Pfizer’s Lipitor. ... [Published StudentNews.ie - May 05 2013]

Entities: Cholesterol, Drugs, Zetia, Merck & Co Inc

First reported May 03 2013 - Updated May 04 2013 - 6 reports

Merck’s Cholesterol Pill Win Is Already Drawing Fire

Home » Blogs » The Food and Drug Administration just approved Liptruzet, a new cholesterol-lowering pill that combines the generically available ingredient available in Pfizer’s Lipitor with Merck’s Zetia. Merck has been working to get the combination ... [Published BioPortfolio - May 04 2013]

Entities: Merck & Co Inc, Cholesterol, Zetia, Biotechnology

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Merck & Co sales slide, $15 billion share buyback unveiled

Merck & Co has suffered a decline in sales and profits in the first quarter, hit by patent expiries on its asthma/allergic rhinitis blockbuster Singulair and disappointing sales for some big-earners, notably the diabetes drug Januvia.Net income came in ... [Published Pharma Times - May 02 2013]

Entities: Merck & Co Inc, Stock Buyback, Ezetimibe, Drugs, sitagliptin

First reported May 01 2013 - Updated May 01 2013 - 1 reports

ZETIA (Ezetimibe) Tablet [Cardinal Health]

Updated Date: May 1, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - May 01 2013]

Entities: Zetia, Ezetimibe, Cardinal Health Inc

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Emerging Cholesterol Pill Could Compete With Amgen, Aegerion

The artery disease that leads to heart attacks and strokes is the biggest killer in the United States. But when it comes to new drugs in development, atherosclerosis is dwarfed by cancer and neurological disorders. Look at the enclosed graph, from the ... [Published Forbes.com - Apr 25 2013]

Entities: Aegerion Pharmaceuticals Inc, Cholesterol, Amgen Inc, Drugs

First reported Apr 22 2013 - Updated Apr 22 2013 - 2 reports

Merck In-Licenses from Xenon - Analyst Blog

Merck & Co. Inc. (MRK) recently announced the in-licensing of Xenon Pharmaceuticals Inc.’s small molecule compounds for a novel target to treat cardiovascular disease.Merck and Xenon’s agreement dates back to 2009 when the companies entered into a strategic ... [Published Quote.com Japan - Apr 22 2013]

Entities: Merck & Co Inc, Xenon, Zetia, Cardiovascular Disease, Vytorin

Quotes

...However, Januvia's sales dipped surprisingly in the first quarter, and more headaches could be onon the way. Johnson & Johnson (NYSE:JNJ) "s newly approved diabetes treatment, Invokana, has already shown some benefits over Januvia in certain clinical trials and could be poised to take a bite out of Merck's sales. Along with the FDA's investigation into pancreatitis concerns for Januvia patients, Merck & Co Inc. (NYSE:MRK)" s star drug isn't having its best time right now. Any threat to its billions of dollars in sales could drastically hurt this firm's future

Merck & Co., Inc. (MRK): Big Payout, Little Flexibility [Published InsiderMonkey.com - May 13 2013]

Commenting on the approval of Liptruzet, Tim Anderson, an analyst at Sanford Bernstein, issued a research note saying that "this is certainly not a ‘high science’ product, yet there is something to be said for a drug that can boast the best LDL cholesterol lowering of any single oral agent currently available" , even better than AstraZeneca's Crestor (atorvastatin)

Surprise as Merck & Co cholesterol combo gets FDA OK [Published Pharma Times - May 07 2013]

...soon-to-be generic, to produce a new patentable product is a pharmaceutical company ploy that should have been transparent to the FDA," says Lipman. "This is especially so in view of the lack of evidence of long-term benefits in the new combination."

FDA approves new cholesterol-lowering pill, but we say skip it [Published Consumer Reports Health Blog - May 06 2013]

But the FDA maintains that high LDL levels are a known risk factor for heart disease. "Liptruzet is a combination of two currently marketed drugs that effectively lower elevated levels of LDL cholesterol" an agency spokeswoman told the NYT...

Merck wins FDA nod for new Zetia-Lipitor combo, despite lack of outcomes benefit [Published FiercePharma - May 06 2013]

More Content

sort by: Date \| Relevance
Pick Your Poison: Overweight or High Cholesterol [Published Motley Fool - 21 hours ago]
FDA Approves Dangerous and Worthless Cholestero... [Published Health Impact News - May 15 2013]
Merck & Co., Inc. (MRK): Big Payout, Little Fle... [Published InsiderMonkey.com - May 13 2013]
Are You Taking This Dangerous Drug? [Published LewRockwell.com - May 13 2013]
Merck Stock: Not a Safe Pick for Dividend Inves... [Published Motley Fool - May 11 2013]
Merck Stock: Not a Safe Pick for Dividend Inves... [Published Motley Fool Discussion Boards - May 11 2013]
Merck Stock: Not a Safe Pick for Dividend Inves... [Published EquityJungle - v0.1 - May 11 2013]
The FDA Approval Of Merck's Cholesterol Lowerer... [Published Forbes.com - May 10 2013]
Merck's Liptruzet: A Cause For Shame? [Published BioPortfolio - May 09 2013]
Co-Q10 deficiency may relate to concern with st... [Published Endocrine Today - May 09 2013]
Merck's Liptruzet: A Cause For Shame? [Published Seeking Alpha - May 09 2013]
Merck's Liptruzet: A Cause For Shame? [Published In the Pipeline - May 09 2013]
FDA Approves Merck’s Cholesterol Combo; Critics... [Published FDA News - May 08 2013]
Merck's Liptruzet Approved in the US - Analyst ... [Published Nasdaq - May 07 2013]
Lipitor Lawsuit News: Rottenstein Law Group Com... [Published PRWeb - May 07 2013]
Merck & Co wins green light in US for Zetia-Lip... [Published PMLive - May 07 2013]
Surprise as Merck & Co cholesterol combo gets F... [Published Pharma Times - May 07 2013]
FDA Approves Merck’s Cholesterol Combo; Critic... [Published FDA News - May 07 2013]
Merck's Liptruzet may mend IMPROVE-IT, but offe... [Published Medical Marketing And Media - May 07 2013]
FDA approves new cholesterol-lowering pill, but... [Published Consumer Reports Health Blog - May 06 2013]
Merck wins FDA nod for new Zetia-Lipitor combo,... [Published FiercePharma - May 06 2013]
FDA approves Merck cholesterol drug [Published Drug Store News - May 06 2013]
MARKET PULSE-Cliffs, Apollo Global, BMC, Intel,... [Published London South East - May 06 2013]
MARKET PULSE-Apollo Global, BMC, Verizon, Intel... [Published London South East - May 06 2013]
FDA Approves Merckâs New Combination... [Published Red Orbit - May 06 2013]
Merck Releases 1Q 2013 Financial Results [Published Individual.com - May 06 2013]
FDA Approves Cholesterol Drug Liptruzet [Published StudentNews.ie - May 05 2013]
Merck & Co., Inc. (MRK), AVEO Pharmaceuticals, ... [Published InsiderMonkey.com - May 04 2013]
Merck’s Cholesterol Pill Win Is Already Drawing... [Published BioPortfolio - May 04 2013]
Persistence pays off: FDA OKs Merck’s combo drug [Published Cardiovascular Business - May 04 2013]

Blogs

sort by: Date \| Relevance
Merck Stock: Not a Safe Pick for Dividend Inves... [Published EquityJungle - v0.1 - May 11 2013] Filed under: Investing Big pharma isn't the first industry many investors envision when dreaming of the big profits to be made from health care stocks. While blockbuster drugs can propel the top big pharma companies to massive profits, these broad ...
Merck's Liptruzet: A Cause For Shame? [Published In the Pipeline - May 09 2013] Vytorin's been discussed several times around here. The combination of Zetia (ezetimibe), the cholesterol absorption inhibitor discovered at Schering-Plough, with Merck's simvastatin looked as if it should be a very effective cholesterol-lowering medication, ...
FDA approves new cholesterol-lowering pill, but... [Published Consumer Reports Health Blog - May 06 2013] Think a pill that packs two cholesterol-lowering drugs in one potent package sounds like a good idea? The Food and Drug administration thinks so. It recently approved the combination of the popular statin drug Lipitor (atorvastatin) with another ...
ZETIA (Ezetimibe) Tablet [Cardinal Health] [Published DailyMed Drug Label Updates for the last seven ... - May 01 2013] Updated Date: May 1, 2013 EST ...
Merck Says A Crucial Vytorin Study Will Continue [Published Pharmalot - Mar 12 2013] A closely watched study of the Vytorin cholesterol pill sold by Merck will continue until September, now that a Data Safety Monitoring Board has completed its planned interim review. Although the drugmaker did not release any data, the move is being ...

Press Releases

sort by: Date \| Relevance
Institutional Investors Recover $688 Million Fr... [Published Marketwire - Breaking News Releases - Feb 14 2013]
The law firms of Bernstein Litowitz Berger & Gr... [Published Financial Services - Jan 25 2013]